Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

NCT06440057 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Carcinoma

Interventions

BIOLOGICAL: ZG006

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd